Deals4 Sept 2025, 03:57 pm
Zydus and Synthon Partner for Ozanimod Capsules in the US Market
AI Summary
Zydus Lifesciences Ltd. and Synthon BV have entered into an exclusive licensing and supply agreement for Ozanimod Capsules, a generic version of ZEPOSIA®, for the US market. Synthon has a pending abbreviated new drug application seeking approval for Ozanimod Capsules, and Zydus will be responsible for the commercialization of the product in the USA. The total addressable market opportunity of Ozanimod Capsules in the U.S is approximately US $637 million.
Key Highlights
- Zydus and Synthon entered into an exclusive licensing and supply agreement for Ozanimod Capsules for the US market.
- Synthon has a pending abbreviated new drug application in the United States for Ozanimod Capsules.
- Zydus will be responsible for the commercialization of the product in the USA.
- Synthon has received tentative approval from the U.S. Food and Drug Administration (FDA) for Ozanimod Capsules.
- The total addressable market opportunity of Ozanimod Capsules in the U.S is approximately US $637 million.